March 2020 FDA Recall Drug by Par Pharmaceutical Inc.
D-1071-2020 - Failed Impurities/Degradation Specification

This Class II drug recall was voluntarily initiated by Par Pharmaceutical Inc. on March 30, 2020 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specification. The product was distributed in Product was distributed within the United States. and the recall is currently terminated.

Recall Number: D-1071-2020

Reason for Recall
Failed Impurities/Degradation Specification: Presence of unknown impurity observed.
Initiated
03-30-2020
Reported
04-08-2020
Quantity
29,352 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Par Pharmaceutical Inc.
Product was distributed within the United States.
Glycopyrrolate Tablets, USP 1 mg, 100-count bottle, Rx only, Dist. by: Par Pharmaceutical, Chestnut Ridge, NY, 10977, U.S.A, Mfg. by: Par Formulations Private Limited, 1/58, Pudupakkam, Kelambakkam - 603 103., Made in India NDC# 49884-0065-01

Batch or Lot Expiration Information

Lot# 32809101, Exp 3/2021